Lori Goldstein, MD, FASCO

Lori Goldstein, MD, FASCO
This physician is not currently rated. Why?

Why is this doctor not rated?


To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Professor Emerita, Department of Hematology/Oncology

NCCN, Breast Cancer Panel Member


Treatment Focus

  • Systemic chemotherapy, hormonal therapy and biologic therapy for early and advanced stage breast cancer
  • Clinical and translational trials in breast cancer

Key Awards

Philadelphia Magazine Top Docs 2020
Medical Oncology

Treatment Philosophy

As a medical oncologist specializing in breast cancer, I believe in providing women the most tailored, state-of-the-art treatment options. That is why I created the Breast Evaluation Center (BEC) when I joined the staff at Fox Chase Cancer Center in 1990.

As the director of the BEC, I work with a team of breast cancer experts, including medical oncologists, surgical oncologists, radiation oncologists, radiologists, pathologists and social workers. Together, we develop a comprehensive treatment plan for patients with early stage breast cancer.

By providing patients with useful information about their treatment options, we are empowering them with the knowledge to make informed decisions about their care. I believe this is very important for women who have been diagnosed with breast cancer, as they can be overwhelmed with the amount of information available today... Expand

Education and Training

Educational Background

  • Fellow, Oncology, Division of Cancer Treatment and Division of Cancer Biology and Diagnosis, National Cancer Institute, Washington, DC
  • Resident, Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • MD, State University of New York Upstate College of Medicine, Syracuse, NY, 1982


  • American Board of Internal Medicine
  • Internal Medicine
  • Medical Oncology


  • National Comprehensive Cancer Network (NCCN)
    • Breast Cancer Panel
  • Program Director, Breast Cancer Symposium, Fox Chase Cancer Center
  • Course Director, Fox Chase Cancer Center Highlights of SABCS CME Program
  • American Association for the Advancement of Science
  • American Association of Cancer Research
  • American Society of Clinical Oncology
  • National Accreditation Program for Breast Cancer Centers
  • Women in Cancer Research

Honors & Awards

  • Philadelphia magazine Top Doctors, 2009-20
  • Best Doctors in America® , 2013-15, 2019-2020, Medical Oncology and Hematology
  • Forbes Magazine list of 27 Top Breast Cancer Oncologists, 2017
  • America’s Top Doctors®,  2012-2017
  • Susan G. Komen "Light of Life Award,” 2014
Patient Stories

Karen Lucas

Breast Cancer

Karen Lucas

Breast Cancer

For more than 20 years, I had been diligent about getting annual mammograms, as well as yearly visits to my OB/GYN. At 65 years old, during a routine mammogram in August 2012, my test showed calcification in both my breasts.

Patti Rose

Breast Cancer

Patti Rose

Breast Cancer

At 36, Patti Rose, a wife and mother to seven children, was shocked to learn she had a rare form of breast cancer. Because her husband works in construction and had done several projects for Fox Chase Cancer Center, they knew right away Fox Chase was the right place for Patti's treatment. At Fox Chase, Patti underwent chemotherapy and radiation therapy, followed by a lumpectomy and additional surgery. The experience was extremely difficult, but Patti credits the staff at Fox Chase for giving her a positive outlook and helping her get through it. Today, she is cancer free and could not be more pleased with the treatment she received. "Fox Chase helped me to be positive. If I didn’t have that connection with doctors and nurses and even the security guard that I would talk to every time I was there, I think I would have felt more afraid," she said. "Knowing all those people were praying for me, thinking of me, and trying to get me through it made me feel like I could overcome it."

Laura Marblestone

Breast Cancer

Laura Marblestone

Breast Cancer

Because Laura Marblestone's mother lost her fight with breast cancer at the age of 43, Laura regularly performed breast self-exams. In 1991, she was diagnosed with encapsulated metastatic carcinoma, and a friend recommended she seek treatment at Fox Chase Cancer Center. After a mestectomy and a round of chemotherapy, Laura was considered cancer free, but in 2006, she found a lump in her right breast; the cancer had returned. She underwent a second mastectomy, chemotherapy, and breast reconstructive surgery. "Even though it took me three months to recover, I would do it again in a heartbeat," she said. "The doctors at Fox Chase were thorough--they didn't leave a stone unturned."

Shari Lynn

Breast Cancer

Shari Lynn

Breast Cancer

In 2002, Shari Lynn's husband, Mark, accepted a new job in another state. Together, Shari and Mark made the decision to move their family from New York to Pennsylvania. Shari was like many other moms in her situation. In preparing for the move, she scheduled routine doctor appointments on Long Island so they would not feel pressured to find new physicians right away.

Marlene Haney

Breast Cancer;  Colorectal Cancer

Marlene Haney

Breast Cancer;  Colorectal Cancer

When Marlene Haney turned 60 in 2013 she decided the best gift she could give herself was a physical she had been putting off. Self–employed and without supplemental health insurance, she says she had not be in a position to see a doctor for over a decade. When her right breast became tender, she realized a trip to the doctor was necessary.


Research Profile

Research Interests

  • Translational studies in breast cancer
  • Development of novel therapeutic strategies in breast cancer
  • Molecular targeting of breast cancer

Selected Publications

Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ, Study G. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clinical breast cancer, 19(2):97-104.e4, 2019. PubMed

Goldstein, LJ, Gray, R, Badve, S, Childs, BH, Yoshizawa, C, Rosley, S, Shak, S, Baehner, FL, Ravdin PM, Davidson, NE, Sledge, GW, Perez, E, Shulman, LN, Martino, S, Sparano, JA: Prognostic Utility of the 21-Gene Assay in Hormone Receptor Positive Operable Breast Cancer with Classical Prognostic Factors and an Integrator of Classical Clinicopathologic and Treatment Information.  JCO, Vol. 26, No. 25, Pg. 4063, September 2, 2008. PubMed

Goldstein, L.J., O’Neill, A., Sparano, J.A., Perez, E.A., Shulman, L.N., Martino, S.,Davidson, N.: Concurrent doxorubicin plus doxetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0-3 positive axillary nodes: results of North American Breast Cancer Intergroup Trial E2197. JCO, Vol. 26, No. 25, Pg. 4092, September 2, 2008. PubMed

Finn, RS, Bengala, C, Strauss, LC, Fairchild, J, Sy, O, Ibrahim, N, Rouche, H, Sparano, J, Goldstein, LJ.:  Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study.  Clin Cancer Res. 2011 Nov 1;17(21):6905-13.

Tevaarwerk AJ, Gray R, Schneider BP, Smith ML, Wagner LI, Fetting J, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in Metastatic Recurrent Breast Cancer after Adjuvant Chemotherapy: Little Evidence for Improvement Over the Past Three Decades. Cancer. 2013 Mar;119(6):1140-8.   PMCID: 3593800

Goldstein, LJ, Tosello-Oliveria, C, Heinrich B, Stemmer SM, Mala C, Kastner S, Bevan P Richters L, Schmalfeldt B, Harbeck N.  A Randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). ASCO 2013 Oral presentation, J. Clin Oncol 31, suppl; Abstract 508.

Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens.  Clinical Breast Cancer, 14(6):396-404, 2014.

Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ.: Risk of Positive Nonsentinel Nodes in Women with 1-2 Positive Sentinel Nodes Related to Age and Molecular Subtype Approximated by Receptor Status.  Breast J Vol. 20(4) 358-363, July 2014. PubMed

Adams S, Gray RJ, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ,  Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS.: Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199.  J Clin Oncol 2014 Sept 20; 32(27):2959-67.  PMID: 25513417.

Silverman, D, Ruth, KJ, Sigurdson, E, Egleston, BL, Goldstein, LJ, Boraas, M, Bleicher R.:  Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal?  Journal of the American College of Surgeons.   Vol 219(3) 534-544 September 2014. PMCID: 4143438.

Matro J, Walia R, Tumelty K, Morrison T, Goldstein LJ.: Bilateral Hypoglossal Nerve Palsy Due to Breast Cancer Skull Base Metastases.  AJHO Vol 10(5) 14-16, Nov. 2014.

Additional Publications


Connect with Fox Chase